Tumours often have areas of hypoxia, which renders cancer cells resistant to many therapies. Recently the anti-malarial drug Atovaquone has been shown to modify the oxygen consumption rate of cancer cells, reducing tumour hypoxia. Non-invasive mapping of tumour hypoxia would be particularly useful for translation of these preclinical findings into a clinical environment. Here, we tested the hypothesis that CEST MRI could be used to visualise changes in tumour hypoxia.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords